knowledge -WSS

knowledge

author：explore 2025-09-06 03:28:08 - browse：46

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Biden warns of ‘dark winter’ during final presidental debate

hotspot

WSS

STAT Summit: Meghan O’Rourke on making chronic illness visible

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Roivant's CEO is a star, but biotech's black hole persists

Cassava Sciences’ Alzheimer’s clinical trials should be halted

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Wikipedia

knowledge

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Will the FTC rein in IQVIA's health data empire?

Alkermes shareholders re

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Medicare proposal to cover medical devices draws a mixed reaction

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Psychedelics group wrestles with new pharma identity

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Moonlake's readout produced a cash windfall. Risks remain

Roche drug slashes death risk in early

hotspot

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

CZI to create biohub to build anti

'Investigate these claims': UFO transparency at center of House hearing

STAT Report: Patient voices and perspectives

The battle over 'scope creep' and who gets to be called 'doctor'

STAT Summit: How researchers deal with rejection

Wikipedia

hotspot

leisure time

focus